|

Peptide vaccine Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
  • Ohio State University Comprehensive Cancer Center1

Indications

  • Cancer2
  • EBV-Related Malignant Neoplasm1
  • Chronic Kidney Disease, Stage 41
  • Chronic Kidney Disease Stage 51
  • Post-Transplant Lymphoproliferative Disorder1

Baltimore, Maryland1 trial

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Johns Hopkins University

Phase 1/2

Columbus, Ohio1 trial

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.